Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8548206 | Food and Chemical Toxicology | 2018 | 45 Pages |
Abstract
In this paper we review the potential of current methodologies (in silico, in vitro degradation, in vitro IgE binding, animal models and clinical studies) to address these outcomes for risk assessment purposes for new proteins, and especially to identify and characterise the risk of sensitization for IgE mediated allergy from oral exposure. Existing tools and tests are capable of assessing potential crossreactivity. However, there are few possibilities to assess the hazard due to de novo sensitization. The only methods available are in vivo models, but many limitations exist to use them for assessing risk. We conclude that there is a need to understand which criteria adequately define allergenicity for risk assessment purposes, and from these criteria develop a more suitable battery of tests to distinguish between proteins of high and low allergenicity, which can then be applied to assess new proteins with unknown risks.
Related Topics
Life Sciences
Agricultural and Biological Sciences
Food Science
Authors
B. Remington, H.C.H. Broekman, W.M. Blom, A. Capt, R.W.R. Crevel, I. Dimitrov, C.K. Faeste, R. Fernandez-Canton, S. Giavi, G.F. Houben, K.C. Glenn, C.B. Madsen, A.K. Kruizinga, A. Constable,